FDAkrav

FDAkrav is a term used in regulatory and industry literature, particularly in Nordic and European contexts, to refer to the set of requirements established by the U.S. Food and Drug Administration (FDA) that products must meet to be marketed in the United States. It is not an official FDA designation, but a shorthand for the agency’s rules across multiple product categories.

The scope of FDAkrav covers drugs and biologics, medical devices, foods and dietary supplements, cosmetics, and tobacco products. For drugs and biologics, it encompasses premarket submissions (such as INDs and NDAs or BLAs; generics via ANDAs), clinical trial standards, labeling, and manufacturing controls. Medical devices follow a pathway that may involve 510(k) clearance, PMAs, or de novo classifications, alongside applicable quality systems. Foods and dietary supplements are regulated under different tracks, including safety, labeling, and manufacturing standards, with rules under the FDA’s broader food program and DSHEA-related provisions. Cosmetics and tobacco products are subject to separate sets of labeling, formulation, and marketing requirements, with tobacco carrying its own premarket processes.

Key components commonly associated with FDAkrav include current good manufacturing practices (cGMP), good laboratory practices (GLP), good clinical practices (GCP), labeling and advertising controls, and post-market surveillance such as adverse event reporting through systems like MedWatch. Regulatory strategy and compliance activities typically involve feasibility assessments, planning of submissions, inspections, imports compliance, and potential enforcement actions for noncompliance.

In practice, FDAkrav influences global development programs, as companies align product development to FDA expectations to facilitate U.S. market access and, by extension, international regulatory acceptance.